白癜风诊疗共识（2021版）

doi:10.35541/cjd.20200785

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 105-109.doi: 10.35541/cjd.20200785

白癜风诊疗共识（2021版）

中国中西医结合学会皮肤性病专业委员会色素病学组

中国中西医结合学会皮肤性病专业委员会色素病学组

收稿日期:2020-08-06 修回日期:2020-11-19 发布日期:2021-01-29
通讯作者: 许爱娥 E-mail:xuaiehz@msn.com

Consensus on the diagnosis and treatment of vitiligo （2021 version）

Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology

Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology

Received:2020-08-06 Revised:2020-11-19 Published:2021-01-29
Contact: Xu Ai′e E-mail:xuaiehz@msn.com

摘要/Abstract

摘要： 【摘要】白癜风是一种常见色素性皮肤病之一，严重影响患者的身心健康。中国中西医结合学会皮肤性病专业委员会色素病学组在2018版白癜风治疗共识的基础上复习近3年白癜风的研究进展，同时结合专家的临床经验，对白癜风的维持治疗和糖皮质激素干预应用进行修订，展望JAK抑制剂治疗，最终达成本共识。

关键词: 白癜风, 治疗, 糖皮质激素类, 光疗法, 钙调神经磷酸酶抑制剂, 专家共识

Abstract: 【Abstract】 Vitiligo is a common depigmented skin disease， which seriously affects the physical and mental health of patients. According to clinical experience of experts as well as research progress in vitiligo in the past 3 years, the Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology revised the statement "Diagnosis and treatment of vitiligo: an expert consensus statement （2018）" in terms of maintenance treatment of vitiligo and application of glucocorticoids, discussed the prospect for Janus kinase （JAK） inhibitors, and finally established this consensus.

Key words: Vitiligo, Therapy, Glucocorticoids, Phototherapy, Calcineurin inhibitor, Expert consensus

中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）[J]. 中华皮肤科杂志, 2021,54(2):105-109. doi:10.35541/cjd.20200785

Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology. Consensus on the diagnosis and treatment of vitiligo （2021 version）[J]. Chinese Journal of Dermatology, 2021, 54(2): 105-109.doi:10.35541/cjd.20200785

参考文献 21

［1］	中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2018版）［J］. 中华皮肤科杂志, 2018,51（4）:247⁃250. doi: 10.3760/cma.j.issn.0412⁃4030.2018.04.001.
［2］	van Geel N, Passeron T, Wolkerstorfer A, et al. Reliability and validity of the Vitiligo Signs of Activity Score （VSAS）［J］. Br J Dermatol, 2020,183（5）:883⁃890. doi: 10.1111/bjd.18950.
［3］	Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity in vitiligo: a systematic review［J］. Autoimmun Rev, 2017,16（9）:937⁃945. doi: 10.1016/j.autrev.2017.07.005.
［4］	Xiang W, Xu A, Xu J, et al. In vivo confocal laser scanning microscopy of hypopigmented macules: a preliminary comparison of confocal images in vitiligo, nevus depigmentosus and postinflammatory hypopigmentation［J］. Lasers Med Sci, 2010,25（4）:551⁃558. doi: 10.1007/s10103⁃010⁃0764⁃2.
［5］	Bae JM, Oh SH, Kang HY, et al. Development and validation of the Vitiligo Extent Score for a Target Area （VESTA） to assess the treatment response of a target lesion［J］. Pigment Cell Melanoma Res, 2019,32（2）:315⁃319. doi: 10.1111/pcmr.12730.
［6］	Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index［J］. Arch Dermatol, 2004,140（6）:677⁃683. doi: 10.1001/archderm.140.6. 677.
［7］	van Geel N, Lommerts J, Bekkenk M, et al. Development and validation of the Vitiligo Extent Score （VES）: an international collaborative initiative［J］. J Invest Dermatol, 2016,136（5）:978⁃984. doi: 10.1016/j.jid.2015.12.040.
［8］	Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference［J］. Pigment Cell Melanoma Res, 2012,25（3）:E1⁃E13. doi: 10.1111/j.1755⁃148X.2012.00997.x.
［9］	Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo［J］. J Am Acad Dermatol, 2017,77（1）:17⁃29. doi: 10.1016/j.jaad.2016.11.010.
［10］	Kanwar AJ, Mahajan R, Parsad D. Low⁃dose oral mini⁃pulse dexamethasone therapy in progressive unstable vitiligo［J］. J Cutan Med Surg, 2013,17（4）:259⁃268. doi: 10.2310/7750.2013. 12053.
［11］	Lee J, Chu H, Lee H, et al. A retrospective study of methylprednisolone mini⁃pulse therapy combined with narrow⁃band UVB in non⁃segmental vitiligo［J］. Dermatology, 2016,232（2）:224⁃229. doi: 10.1159/000439563.
［12］	林洁, 樊奇敏, 许爱娥. 窄谱中波紫外线治疗白癜风平台期相关研究［J］. 临床皮肤科杂志, 2016,45（6）:465⁃468.
［13］	Khullar G, Kanwar AJ, Singh S, et al. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB⁃UVB vs. NB⁃UVB alone in the treatment of vitiligo: a 24⁃week prospective right⁃left comparative clinical trial［J］. J Eur Acad Dermatol Venereol, 2015,29（5）:925⁃932. doi: 10.1111/jdv.12726.
［14］	Hu W, Xu Y, Ma Y, et al. Efficacy of the topical calcineurin inhibitors tacrolimus and pimecrolimus in the treatment of vitiligo in infants under 2 years of age: a randomized, open⁃label pilot study［J］. Clin Drug Investig, 2019,39（12）:1233⁃1238. doi: 10.1007/s40261⁃019⁃00845⁃x.
［15］	Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo［J］. Br J Dermatol, 2001,145（3）:476⁃479. doi: 10.1046/j.1365⁃2133.2001.04381.x.
［16］	de Menezes AF, Oliveira de Carvalho F, Barreto RS, et al. Pharmacologic treatment of vitiligo in children and adolescents: a systematic review［J］. Pediatr Dermatol, 2017,34（1）:13⁃24. doi: 10.1111/pde.13024.
［17］	Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus［J］. JAMA Dermatol, 2015,151（6）:594⁃599. doi: 10.1001/jamadermatol. 2014.4305.
［18］	Oiso N, Kawada A. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo［J］. Pediatr Dermatol, 2012,29（5）:671⁃672. doi: 10.1111/j.1525⁃1470.2011.01559.x.
［19］	Passeron T. Medical and maintenance treatments for vitiligo［J］. Dermatol Clin, 2017,35（2）:163⁃170. doi: 10.1016/j.det.2016. 11.007.
［20］	Mohammad TF, Al⁃Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:879⁃888. doi: 10.1016/j.jaad.2016.12.041.
［21］	Rosmarin D , Pandya A G , Lebwohl M , et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial［J］. The Lancet, 2020,396（10244）:110⁃120. doi:10.1016/S0140⁃6736（20）30609⁃7.

[1]	张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767.
[2]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[3]	付超吴姣娜郎文超高菲牛贵业边培雯高敏虹司晓青辛琳琳. 皮肤镜检查在评估白癜风疾病活动性中的作用[J]. 中华皮肤科杂志, 2022, 55(3): 268-271.
[4]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[5]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[6]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[7]	艾尼瓦尔·塔力甫熊成热甫哈提·赛买提玉苏甫·买提努尔吐尔逊·吾甫尔阿肯木江·艾尔肯居来提·阿不都瓦衣提买买提艾力·卡的. 生物信息学鉴定和分析白癜风差异表达基因[J]. 中华皮肤科杂志, 2022, 0(2): 20200391-e20200391.
[8]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694.
[9]	焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384.
[10]	王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115.
[11]	李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631.
[12]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[13]	包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156.
[14]	郭静杨景煜丁黎刘明明侯晶梅蒲小霞孙嘉昱李向花. 长脉宽1 064 nm Nd：YAG激光联合含滇山茶和三七等提取物的外用乳剂治疗黄褐斑的疗效[J]. 中华皮肤科杂志, 2022, 55(1): 61-64.
[15]	陈怡, 宋秀祖. 瞬时受体电位通道在黑素细胞中的作用及相关疾病研究[J]. 中华皮肤科杂志, 2022, 0(1): 20200958-e20200958.

白癜风诊疗共识（2021版）

Consensus on the diagnosis and treatment of vitiligo （2021 version）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

Metrics

本文评价

推荐阅读 10